Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy
- PMID: 31995247
- DOI: 10.1002/jso.25859
Prognostic role of tumor mutation burden in hepatocellular carcinoma after radical hepatectomy
Abstract
Background and aim: This study aimed to assess the potential relationship between tumor mutation burden (TMB) and the recurrence risk of hepatocellular cancer (HCC) after curative resection and tried to develop a reliable TMB based nomogram.
Methods: This retrospective study was conducted in 128 patients (40 patients suffered from a recurrence of HCC) who had received radical hepatectomy by the same surgical team. A nomogram model was constructed using the R and EmpowerStats software.
Results: TMB was not associated with maximum tumor size and the presence of microvascular invasion (MVI). In the whole population or subgroups, the recurrence-free survival (RFS) rate was significantly lower in the TMB high group. In multivariate analysis, TMB (hazard ratio [HR], 10.12; 95% confidence interval [CI], 5.03-20.31; P < .001), large tumor diameter (HR, 2.91; 95% CI, 1.51-5.63; P = .001), presence of MVI (HR, 1.93; 95% CI, 1.03-3.65; P = .042) were independent predictors of RFS. The predictive power of the nomogram integrating TMB, tumor size and MVI was higher than model only incorporating tumor size and MVI.
Conclusion: This study demonstrated for the first time that higher TMB was associated with poor prognosis in patients with HCC who had received curative resection, and a TMB based nomogram model had a well predictive performance for RFS in this population.
Keywords: HCC; MVI; nomogram; prognosis; tumor mutation burden.
© 2020 Wiley Periodicals, Inc.
Similar articles
-
Nomogram to Assist in Surgical Plan for Hepatocellular Carcinoma: a Prediction Model for Microvascular Invasion.J Gastrointest Surg. 2019 Dec;23(12):2372-2382. doi: 10.1007/s11605-019-04140-0. Epub 2019 Feb 28. J Gastrointest Surg. 2019. PMID: 30820799
-
Development and Validation of a Model Including Distinct Vascular Patterns to Estimate Survival in Hepatocellular Carcinoma.JAMA Netw Open. 2021 Sep 1;4(9):e2125055. doi: 10.1001/jamanetworkopen.2021.25055. JAMA Netw Open. 2021. PMID: 34515782 Free PMC article.
-
Preoperative tumor abnormal protein is a promising biomarker for predicting hepatocellular carcinoma oncological outcome following curative resection.J Cancer Res Ther. 2022 Dec;18(7):2021-2026. doi: 10.4103/jcrt.jcrt_58_22. J Cancer Res Ther. 2022. PMID: 36647965
-
Role of microvascular invasion in early recurrence of hepatocellular carcinoma after liver resection: A literature review.Asian J Surg. 2024 May;47(5):2138-2143. doi: 10.1016/j.asjsur.2024.02.115. Epub 2024 Mar 5. Asian J Surg. 2024. PMID: 38443255 Review.
-
Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis.Clin Res Hepatol Gastroenterol. 2020 Apr;44(2):142-154. doi: 10.1016/j.clinre.2019.06.012. Epub 2019 Jul 11. Clin Res Hepatol Gastroenterol. 2020. PMID: 31303533
Cited by
-
Microscopic Portal Vein Invasion in Relation to Tumor Focality and Dimension in Patients with Hepatocellular Carcinoma.J Gastrointest Surg. 2022 Feb;26(2):333-340. doi: 10.1007/s11605-021-05126-7. Epub 2021 Sep 10. J Gastrointest Surg. 2022. PMID: 34506030
-
T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis via integrating single-cell RNA-seq and bulk RNA-sequencing.Front Immunol. 2023 Mar 15;14:1137025. doi: 10.3389/fimmu.2023.1137025. eCollection 2023. Front Immunol. 2023. PMID: 37006257 Free PMC article.
-
Analysis and experimental validation of the innate immune gene PSMD1 in liver hepatocellular carcinoma and pan-cancer.Heliyon. 2023 Oct 18;9(11):e21164. doi: 10.1016/j.heliyon.2023.e21164. eCollection 2023 Nov. Heliyon. 2023. PMID: 37928041 Free PMC article.
-
Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma.Biosci Rep. 2022 Feb 25;42(2):BSR20212304. doi: 10.1042/BSR20212304. Biosci Rep. 2022. PMID: 35075482 Free PMC article. Review.
-
Expert Insights on Current Treatments for Hepatocellular Carcinoma: Clinical and Molecular Approaches and Bottlenecks to Progress.J Hepatocell Carcinoma. 2022 Dec 7;9:1247-1261. doi: 10.2147/JHC.S383922. eCollection 2022. J Hepatocell Carcinoma. 2022. PMID: 36514693 Free PMC article. Review.
References
REFERENCES
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424.
-
- European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908-943.
-
- Bhangui P, Allard MA, Vibert E, et al. Salvage versus primary liver transplantation for early hepatocellular carcinoma: do both strategies yield similar outcomes? Ann Surg. 2016;264(1):155-163.
-
- Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy. Pharmacol Ther. 2019;194:84-106.
-
- Fancello L, Gandini S, Pelicci PG, Mazzarella L. Tumor mutational burden quantification from targeted gene panels: major advancements and challenges. J Immunother Cancer. 2019;7(1):183.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical